BiotechTube
March Biosciences

March Biosciences

Houston, United States· Est.
march.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

March Biosciences is a private, clinical-stage biotech founded in 2020 and headquartered in Houston, Texas. The company is developing a CAR-T cell therapy platform with an initial focus on CD5 as a target for treating relapsed/refractory T-cell malignancies, an area of high unmet need. It has advanced its lead candidate, MB-105, into a Phase 2 clinical trial, building on foundational research from Baylor College of Medicine. The company emphasizes a streamlined manufacturing process and a team with deep cell therapy expertise.

OncologyHematological Cancers

Technology Platform

CAR-T cell therapy platform focused on 'target-unlock' for challenging antigens, emphasizing cell quality and a streamlined manufacturing process without additional gene editing.

Opportunities

MB-105 addresses a high unmet need in relapsed/refractory T-cell lymphoma, a market with limited competition and potential for premium pricing.
Success could validate the 'target-unlock' platform, enabling expansion into other CD5+ malignancies and creating significant partnership or acquisition interest.

Risk Factors

High clinical risk targeting CD5 due to potential for on-target, off-tumor toxicity and T-cell aplasia.
The company faces significant concentration risk with a single asset in Phase 2 and depends on raising additional capital as a pre-revenue entity.

Competitive Landscape

The T-cell lymphoma space is emerging with limited approved targeted therapies. Competition includes other biotechs developing CAR-Ts (e.g., against other targets like CD7) and bispecific antibodies. March's differentiation lies in its specific CD5 CAR-T approach and focus on cell quality.

More companies in Cell & Gene Therapy →More companies in United States →